Vyepti®
Vyepti® (eptinezumab-jjmr) is a calcitonin-gene related peptide antagonist (CGRP) inhibitor that is used to prevent migraines in adults. Vyepti (pronounced VEE ep tee) was approved for use by the Food and Drug administration (FDA) in February 2020 and became available in April.
For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.
MANUFACTURER: Lundbeck Seattle Biopharmaceuticals |
CLASS: Biologics (CGRP ligand) |
WHAT IT TREATS: |
PRESCRIBED BY: Neurologists |
HOW ADMINISTERED: IV Infusion |
FREQUENCY: Every three months |
Length of infusion: 30 mins |
FOR MORE INFORMATION: |